Thursday, January 21, 2021
Mitochondrial Health

Targeting Tau in Alzheimer's Disease

Professor Claude Wischik, CEO TauRx Therapeutics Ltd, and Dr Sonya Miller, Medical Oversight Lead, present these educational materials created by non-profit organisation BrainMind. The scientific illustrations bring to life the current research into the role of tau in Alzheimer’s Disease, therapeutic targets in new research, and the mode of action of TauRx’s lead compound, hydromethylthionine or LMTX.


Similar Posts

One thought on “Targeting Tau in Alzheimer's Disease

Leave a Reply

Your email address will not be published. Required fields are marked *